Extended-interval dosing of natalizumab linked to lower risk of PMLFebruary 22, 2018Multiple Sclerosis
Study identifies characteristics that may constitute the MS prodromeFebruary 11, 2018Multiple Sclerosis
Nearly half of MS patients treated by primary docs miss out on medsFebruary 9, 2018Multiple Sclerosis
VIDEO: Teriflunomide and dimethyl fumarate are comparable in relapsing-remitting MSFebruary 9, 2018Multiple Sclerosis
‘Real-world evidence’ used to compare agents for relapsing-remitting MSFebruary 7, 2018Multiple Sclerosis
